Moderna boosts unicorn status with a whopping $500M raise and $7B valuation
The biotech world’s biggest unicorn just raised $500 million, bringing its total haul to about $2.5 billion from partnerships and investors while valuing the company at close to $7 billion.
This year Moderna will burn through about $450 million, the executive team tells me today. And with this new financing, the company has three years of runway — plenty of time to figure out the right timing for an eventual IPO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.